人福医药(600079.SH)：左炔诺孕酮片获得药品注册证书

Core Viewpoint - The approval of Levonorgestrel tablets by the National Medical Products Administration marks a significant milestone for the company, enabling it to sell this emergency contraceptive in the domestic market, which is expected to positively impact its product line and overall business performance [1]. Group 1 - The company’s subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., has received the drug registration certificate for Levonorgestrel tablets [1]. - Levonorgestrel tablets are indicated for emergency contraception in women [1]. - The approval enhances the company's product portfolio, which is anticipated to bring positive effects on its sales and market presence [1].